552c7ae14ClaimPlacebo-controlled trials should be required before approving new medicinesAgreeDisagree
552c7ae14ClaimNew medicines should have to outperform existing treatments before approvalAgreeDisagree
552c7ae14ClaimGovernments should license publicly funded drug patents to competitors when prices are unaffordableAgreeDisagree
552c7ae14ClaimMedical research grants should be allocated by lottery among proposals that meet a quality thresholdAgreeDisagree
552c7ae14ClaimConsenting adults should be allowed to join human infection trials without an effective rescue treatmentAgreeDisagree
552c7ae14ClaimPublicly funded medical research should be freely available immediately upon publicationAgreeDisagree
552c7ae14ClaimDrugs for serious illnesses should qualify for accelerated approval based on biomarkers before patient benefit is provenAgreeDisagree
552c7ae14ClaimTerminally ill patients should be allowed experimental drugs before trials establish effectivenessAgreeDisagree
552c7ae14ClaimResearch on live plague strains in anti-plague institutes poses an unacceptable public safety riskAgreeDisagree
552c7ae14ClaimThe lack of an approved vaccine justifies the emergency deployment of experimental treatmentsAgreeDisagree
552c7ae14ClaimThe FDA should reject clinical trials that use outdated control arms for drug approvalsAgreeDisagree
552c7ae14ClaimTying Medicare drug prices to international benchmarks will lower patient costs without reducing access to treatmentsAgreeDisagree
552c7ae14ClaimThe finalized international pricing model covers too few drugs to meaningfully reduce Medicare spendingAgreeDisagree
552c7ae14ClaimExempting drugmakers that struck voluntary price deals from the mandatory pricing model undermines the programAgreeDisagree
552c7ae14ClaimPharmaceutical companies are right to challenge the mandatory pricing model in courtAgreeDisagree
552c7ae14ClaimDrugmakers should only claim superiority over competitors using head-to-head clinical trialsAgreeDisagree